The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Open accessAbstract
Antimalarial Drug Candidate: Spiroindolones were discovered as promising antimalarial drug candidates through a high-throughput screening approach that should be applicable to a range of neglected infectious diseases. Rottmann et al. (p. 1175 ; see the Perspective by Wells ) present the preclinical profile for an optimized spiroindolone drug candidate, NITD609. They obtained evidence for a decrease in drug sensitivity in strains of the malaria parasite Plasmodium falciparum bearing amino acid mutations in the P-type ATPase, indicating possible mechanisms of action and/or resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
Self-citationQinghaosu (Artemisinin): The Price of Success
White, N. J. (2008) · Science · doi:10.1126/science.1155165 · Cited by 954
Malaria: progress, perils, and prospects for eradication
Greenwood, B. M., Fidock, D. A., Kyle, D. E., Kappe, S. H. I., Alonso, P. L., Collins, F. H., & Duffy, P. E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33996 · Cited by 709
Self-citation
Cited by
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
Qiu, D., Pei, J. V., Rosling, J. E. O., Thathy, V., Li, D., Xue, Y., Tanner, J. D., Penington, J. S., Aw, Y. T. V., Aw, J. Y. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33403-9 · Cited by 70
Self-citationTse, E. G., Aithani, L., Anderson, M., Cardoso-Silva, J., Cincilla, G., Conduit, G. J., Galushka, M., Guan, D., Hallyburton, I., Irwin, B. W. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00313 · Cited by 18
Ling, D. B., Nguyen, W., Looker, O., Razook, Z., McCann, K., Barry, A. E., Scheurer, C., Wittlin, S., Famodimu, M. T., Delves, M. J., et al. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00138 · Cited by 6
Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate
Li, H., Ji, S., Ariefta, N. R., Galon, E. M. S., El-Sayed, S. A., Do, T., Jia, L., Sakaguchi, M., Asada, M., Nishikawa, Y., et al. (2025) · eLife · doi:10.7554/elife.101128 · Cited by 1
Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate
Li, H., Ji, S., Ariefta, N. R., Galon, E. M. S., El-Sayed, S. A., Do, T., Jia, L., Sakaguchi, M., Asada, M., Nishikawa, Y., et al. (2025) · eLife · doi:10.7554/elife.101128.4 · Cited by 1
Metadata
- Authors
- Rottmann, M., McNamara, C., Yeung, B. K. S., Lee, M. C. S., Zou, B., Russell, B., Seitz, P., Plouffe, D. M., Dharia, N. V., Tan, J., Cohen, S. B., Spencer, K. R., González-Páez, G. E., Lakshminarayana, S. B., Goh, A., Suwanarusk, R., Jegla, T., Schmitt, E. K., Beck, H.-P., Brun, R., Nosten, F., Renia, L., Dartois, V., Keller, T. H., Fidock, D. A., Winzeler, E. A., & Diagana, T. T.
- Venue
- Science
- Published
- 2010-09-03
- Volume
- 329
- Issue
- 5996
- Pages
- 1175-1180
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2014429457
- Cited by
- 1,206
- References
- 3
- FWCI
- 72.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
